NCT01426529
Caveolin-1 and Vascular Dysfunction
StatusActive, Not Recruiting
PhasePhase 1
SponsorBrigham and Women's Hospital
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 15, 2026 to Oct 15, 2027
- Eligibility criteria revised
- Site details revised
- Publications: details revised at 1 of 1 entry
- Notable Primary and study completion dates: Oct 15, 2022 to Oct 15, 2026v7
- Notable Primary and study completion dates pushed to Oct 15, 2022
- Study arms: 0 to 2
- Minor Study completion date: Oct 15, 2017 to Oct 15, 2019v5
Notable Phase: Not applicable to Phase 1v4 Show 4 more changesShow less
- Primary and study completion dates: Oct 2015 to Oct 15, 2017
- Trial status: Recruiting to Active, Not Recruiting
- Start date: Oct 2010 to Oct 1, 2010
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Genetic Variation at the Caveolin-1 Locus
Timeframe: 5 years
Arms and interventions
major allele homozygousExperimental
we will compare this arm with the minor allele carrier arm
minor allele carriersExperimental
we will compare this arm with the major allele homozygous arm
Drugs: Para-aminohippuric Acid, Angiotensin II, Norepinephrine
Sites
1 site in 1 country
- Brigham and Women's HospitalBoston, Massachusetts, United States